What is the difference between Ogivri and Herceptin?
Ogivri (trastuzumab-dkst) is a biosimilar to Herceptin (trastuzumab).
A biosimilar is a biological product that is FDA-approved and highly similar to a biologic already FDA-approved with no clinically meaningful differences in terms of safety and effectiveness from the reference product.
What Are Biosimilars? Top Facts You May Not Know
Ogivri and Herceptin are both used for the treatment of patients with HER2+ breast cancer or HER2-overexpressing metastatic stomach cancer (metastatic gastric or gastroesophageal junction adenocarcinoma).
Ogivri has not been approved as an interchangeable biosimilar, meaning the pharmacist cannot substitute Ogivri for Herceptin without consulting the prescriber.
Ogivri was the first approved biosimilar to Herceptin.
Herceptin (trastuzumab) Biosimilars
Related medical questions
- What are biosimilar drugs?
- What are the biosimilars of Herceptin?
- What is the difference between Herceptin and Herceptin Hylecta?
- What is the difference between Herzuma and Herceptin?
- What biosimilars have been approved in the United States?
- How long can I stay on Herceptin?
- What is Herceptin? Is Herceptin a chemo drug? How does it work?
- How long can you stay on Herceptin and Perjeta?
- How long does Herceptin stay in your body?
- What happens after Herceptin treatment?
- What is tdm1 chemotherapy?
Drug information
Related support groups
- Herceptin (18 questions, 30 members)
- Ogivri (4 questions, 4 members)
- Trastuzumab (13 questions, 4 members)
- Breast Cancer (115 questions, 302 members)
- Gastric Cancer (11 questions, 12 members)